AstraZeneca has announced a restructuring programme expected to generate approximately $1.5 billion in benefits as the pharmaceutical company seeks to...
ovartis has raised its full-year 2026 core operating income outlook after stronger third-quarter performance, while recognising a $1.9bn impairment charge...
Merck and Moderna have reported that their investigational personalised mRNA cancer therapy, intismeran autogene, combined with KEYTRUDA (pembrolizumab), reduced the...
Microsoft says its artificial intelligence diagnostic system, MAI-DxO, achieved higher diagnostic accuracy than generalist physicians across two medical case benchmarks,...